Innate Pharma share price logo

Innate Pharma

NASDAQ: IPHA

$1.40

-0.03

(-1.75%)

as on

Innate Pharma Stock Performance

as on November 6, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.38
    $1.43
    downward going graph

    1.43%

    Downside

    2.14%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.17
    $2.71
    downward going graph

    16.43%

    Downside

    93.57%

    Upside

    downward going graph

Innate Pharma share price movements today

Previous Close
$1.43
Open
$1.43
Volume
243.6K
Market Cap
$148.6M
Day's Low - High
$1.38 - $1.43
52 Week Low - High
$1.17 - $2.71

Innate Pharma Historical Returns

1 Month Return
-9.81 %
3 Month Return
-19.49 %
1 Year Return
-21.7 %
3 Year Return
-46.02 %
5 Year Return
-74.32 %

Innate Pharma Stock Fundamentals & Key Indicators

Check Innate Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$148.6M

EPS (TTM)

-0.51

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.75%

PE Ratio (TTM)

-2.34

Industry PE ratio

-3.24

PEG Ratio

-0.32

EBITDA

-51.9M

Revenue (TTM)

1.1M

Profit Margin

1770.35%

Return On Equity TTM

152.56%

Innate Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Innate Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Innate Pharma image
Innate Pharma
Buy$148.6M-74.32%-2.341770.35%0.00%
Moderna image
Moderna
Neutral$91.2B9.03%-28.63-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$141.7B192.56%32.2786.04%0.00%
Regeneron image
Regeneron
Buy$99.4B52.18%20.7385.77%0.38%

Stock Returns calculator for Innate Pharma Stock including INR - Dollar returns

The Innate Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Innate Pharma investment value today

Current value as on today

₹82,064

Returns

-₹17,936

(-17.94%)

Returns from Innate Pharma Stock

-₹23,077 (-23.08%)

Dollar Impact

₹5,141 (+5.14%)

Analyst Recommendation on Innate Pharma Stock

Based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for Innate Pharma. Average target price of $6.67

Innate Pharma Share Price Target

Get share price movements and forecasts by analysts on Innate Pharma.

What analysts predicted

79.01%UPSIDE

Target Price

$6.67

Current Price

$1.4

Analyzed by

2 Analysts

High

$9

Target

$6.67

Low

$7

Innate Pharma target price $6.67, a slight upside of 79.01% compared to current price of $1.4. According to 2 analysts rating.

Indian Investors' Interest in Innate Pharma Stock

Search interest for Innate Pharma Stock has decreased by -76% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-76% versus previous 30 day period

Innate Pharma Quarterly Profit & Loss

All numbers in Millions USD

Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Jun 2026
Total Revenue
2
41
8
35
16
12
0
4
-2
3
Gross Profit
-10
28
-5
19
-3
-16
29
-15
18
-
Operating Income
-30
4
-28
-5
-7
-26
-25
-25
-27
-21
EBITDA
-26
6
-10
0
-10
-25
-21
-24
-30
-21
Interest Expense
-
-
0
0
3
0
0
-
2
0
Depreciation
2
2
2
3
1
1
0
0
0
0
Income Before Tax
-29
2
-68
-3
-4
-24
-24
-21
-27
-22
Income Tax Expense
-7
-4
-3
-4
-
-
-
-
-2
-2
Net Income
-29
6
-64
1
-9
-24
-24
-21
-27
-19
Net Profit Margin
-361.80%
69.77%
-60.71%
55.50%
-18.88%
-135.53%
10634.78%
-322.22%
-889.87%
0.00%

Innate Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
32
79
68
69
12
57
51
12
2
Gross Profit
-34
10
23
20
-22
6
5
12
2
Operating Income
-39
5
-27
1
-47
-57
-12
-51
-53
EBITDA
-35
12
18
57
-43
-12
-1
-46
-43
Interest Expense
0
0
0
0
0
0
0
0
0
Depreciation
4
7
16
56
4
45
5
1
5
Income Before Tax
-48
2
-20
0
-45
-57
-7
-49
-49
Income Tax Expense
0
0
0
-
-
-
-
-
-
Net Income
-48
3
-20
-63
-52
-58
-7
-49
-49
Net Profit Margin
-105.33%
12.94%
34.53%
28.76%
-184.12%
10.42%
10.83%
100.00%
100.00%

Innate Pharma Quarterly Cash Flow

All numbers in Millions USD

Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Jun 2026
Net Income
-21
6
-64
1
-9
-24
-24
-23
-27
-19
Operating Cash Flow
-27
1
-20
-11
-21
3
-9
-34
-23
-21
Investing Cash Flow
0
0
2
0
20
0
8
7
0
2
Financing Cash Flow
28
0
-1
-1
0
-4
-1
11
-3
-2
Change in Cash
0
0
-18
-12
0
69
-3
-5
-25
-22

Innate Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-48
3
-20
-63
-52
-58
-7
-49
-7
Operating Cash Flow
-48
-32
34
-51
-58
-19
-32
-6
-32
Investing Cash Flow
-29
24
-62
-13
0
1
20
9
20
Financing Cash Flow
0
61
77
-1
26
-1
-1
-6
-1
Change in Cash
-76
52
50
-66
-33
-19
-13
-4
-13

Global Institutional Holdings in Innate Pharma

Check out the Institutions with significant holdings in Innate Pharma.

Funds
Holdings
Caitong International Asset Management Co., Limited.
0.00%
Exchange Traded Concepts, LLC
0.00%
GAMMA Investing LLC
0.00%
Sageview Advisory Group LLC
0.00%
Citadel Advisors Llc
0.01%
See all

Innate Pharma News & Key Events

  • img

    Today's Timeline - 03 April

    Fri, 10:31 AM

    -

    Innate Pharma to hold one-on-one investor meetings at Kempen Life Sciences Conference on April 15-16, 2026.

Insights on Innate Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, -2.07M → 3.15M (in $), with an average increase of 165.7% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -27.62M → -19.88M (in $), with an average increase of 38.9% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 892.4% return, outperforming this stock by 914.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 235.0% return, outperforming this stock by 281.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, IPHA stock has moved down by -46.2%

About Innate Pharma

Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
OrganisationInnate Pharma
Headquarters117, Avenue de Luminy, Marseille, PAC, 13009, FR
IndustryBiotechnology
CEOJonathan E. Dickinson

Key Management of Innate Pharma

Name

Title

Mr. Alessandro Moretta M.D., Ph.D.

Founder

Mr. Frederic Lombard M.B.A.

Senior VP & CFO

Dr. François Romagné Ph.D.

Founder

Mr. Yannis Morel Ph.D.

Executive VP & COO

Dr. Marc Bonneville Ph.D.

Founder

Mr. Jean Jacques Fournié Ph.D.

Founder

Ms. Stephanie Cornen

Vice President of Investor Relations, Communication & Commercial Strategy

Ms. Odile Belzunce

VP, Chief of Compliance & Operations Officer and Interim Head of HR

Ms. Claire de Saint Blanquat

VP of Legal & Corporate Affairs and Secretary of the Supervisory Board

Mr. Jonathan E. Dickinson B.Sc., M.B.A.

CEO & Director

FAQs

What is Innate Pharma share price today?

Innate Pharma share price today is $1.40 as on at the close of the market. Innate Pharma share today touched a day high of $1.43 and a low of $1.38.

What is the 52 week high and 52 week low for Innate Pharma share?

Innate Pharma share touched a 52 week high of $2.71 on and a 52 week low of $1.17 on . Innate Pharma stock price today i.e. is closed at $1.40,which is 48.34% down from its 52 week high and 19.66% up from its 52 week low.

What is Innate Pharma's market capitalisation today?

Innate Pharma market capitalisation is $0.00T as on .

How to invest in Innate Pharma Stock (IPHA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Innate Pharma on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Innate Pharma Stock (IPHA) from India?

Indian investors can start investing in Innate Pharma (IPHA) shares with as little as ₹94.4749984741211 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.75 in Innate Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Innate Pharma share’s latest price of $1.40 as on November 6, 2026 at 8:45 am IST, you will get 7.1429 shares of Innate Pharma. Learn more about fractional shares .

What are the returns that Innate Pharma has given to Indian investors in the last 5 years?

Innate Pharma stock has given -74.32% share price returns and 27.92% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?